Pacific Growth Equities Life Sciences Growth Conference on June 13th and
Needham & Company's Fifth Annual Biotechnology Conference on June 14th
SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals,
Inc. (Nasdaq: ANDS) announced today that it will present at the Pacific
Growth Equities Life Sciences Growth Conference 2006 on Tuesday, June 13,
2006 at 8:30 a.m. Pacific Daylight Time (11:30 a.m. Eastern Daylight Time)
at the InterContinental Mark Hopkins Hotel in San Francisco. Kleanthis G.
Xanthopoulos, Ph.D., Anadys' President and Chief Executive Officer, will
present an overview of Anadys and its clinical development and discovery
programs.
Anadys will also present at the Needham & Company's Fifth Annual
Biotechnology Conference on Wednesday, June 14 at 1:00 p.m. EDT (10:00 a.m.
PDT) at the New York Palace Hotel in New York City. Devron R. Averett,
Ph.D., Anadys' Chief Scientific Officer, will present an overview of Anadys
and its clinical development and discovery programs.
Both presentations will be simultaneously webcast and can be accessed
on the Company's website at http://www.anadyspharma.com. Listeners are encouraged
to visit the website approximately five minutes prior to each corporate
presentation to download or install any necessary software. A replay of the
presentations will become available approximately one hour after the live
webcast concludes and will be archived and available until June 27, 2006
and June 28, 2006, respectively.
About Anadys
Anadys Pharmaceuticals, Inc., http://www.anadyspharma.com, is a
biopharmaceutical company committed to advancing patient care by
discovering, developing and commercializing novel small molecule medicines
for the treatment of hepatitis, other serious infections, and cancer. The
Company has core expertise in Toll-Like Receptor-based small molecule
therapeutics and structure-based drug design coupled with medicinal
chemistry. Anadys' clinical development programs include ANA975 for the
treatment of HCV and HBV, and ANA380 for the treatment of HBV. In addition,
Anadys' therapeutic platform is designed to advance a strong and continual
pipeline of drug candidates into the clinic.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors, which may cause Anadys' actual results to be materially different
from historical results or from any results expressed or implied by such
forward-looking statements. In particular, the results of initial clinical
trials may not be predictive of future results, and Anadys cannot provide
any assurances that any of its product candidates will have favorable
results in future clinical trials or receive regulatory approval. In
addition, Anadys' results may be affected by risks related to its
collaborative relationships with Novartis and LG Life Sciences, competition
from other biotechnology and pharmaceutical companies, its effectiveness at
managing its financial resources, its ability to successfully develop and
market products, the level of effort that its collaborative partners devote
to development and commercialization of its product candidates,
difficulties or delays in its clinical trials, difficulties or delays in
manufacturing its clinical trials materials, the scope and validity of
patent protection for its products, regulatory developments involving
future products and its ability to obtain additional funding to support its
operations. These and other factors that may cause actual results to differ
are more fully discussed in the "Risk Factors" section of Anadys' Form 10-Q
for the quarter ended March 31, 2006. All forward-looking statements are
qualified in their entirety by this cautionary statement. Anadys is
providing this information as of this date and does not undertake any
obligation to update any forward-looking statements contained in this
document as a result of new information, future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.
 back to top
Related links:
http://www.anadyspharma.com
CONTACT:
Vince Reardon, Sr. Director, Investor
Relations & Corporate Communications of Anadys Pharmaceuticals,
Inc., +1-858-530-3653, vreardon@anadyspharma.com
|
